Seegene said that it has won a bid to supply Allplex Entero-DR, an intestinal bacteria antibiotic resistance test kit, to ESTAR, a hospital group based in Tuscany, Italy.
The Korean company plans to supply 10 billion won ($8.5 million) worth of equipment to the hospital group for three years through Arrow Diagnostics, its local subsidiary.
"The agreement is significant as it is the first time that the Italian antibiotic resistance test method has changed from the conventional culture test to a molecular diagnosis method using our test kit," the company said.
Seegene’s device can obtain results in less than three hours, providing greater accuracy and speed than the culture test, which took three days to finalize.
Also, the multiplex technology can detect a large number of genotypes in one test, which is economically beneficial than competing products, the company added.
As of now, the culture method is the primary method for testing antibiotic resistance. However, the molecular diagnostic is attracting attention as it can lower the unit cost when a large number of inpatients are at risk in hospitals.
According to Seegene, the market for diagnosis of hospital-acquired infection (HAI), mainly caused by antibiotic resistance, is expected to reach $11.6 billion by 2022.
The company expects that its test method will reduce the pain of patients and improve the efficiency of hospital operation.
"As the importance of preventive medicine and precision medical care is increasing day by day, the medical community's preference for leading molecular diagnosis is increasing," Seegene CEO Chun Jong-yoon said. "Starting with the contract in Italy, we plan to speed up our advance to the antibiotic resistance testing market in Europe."
<© Korea Biomedical Review, All rights reserved.>